Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$4.61 +0.7%	$4.04	$1.58 ▼ $7.27	$410.68M	-0.6	1.23 million shs	989,958 shs
BHST BioHarvest Sciences	$6.44 -0.5%	$5.98	$6.41 ▼ $7.38	$105.79M	0.8	18,029 shs	4,673 shs
SAGE Sage Therapeutics	$6.56 -2.2%	$7.50	$4.62 ▼ $13.47	$410.79M	0.2	1.23 million shs	997,942 shs
SANA Sana Biotechnology	$1.81	$1.93	$1.26 ▼ $9.49	$410.37M	1.75	3.31 million shs	4.86 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	-13.35%	+32.09%	+21.32%	+138.86%
BHST BioHarvest Sciences	0.00%	-1.38%	+16.04%	+11.61%	+643,999,900.00%
SAGE Sage Therapeutics	0.00%	-10.14%	-5.07%	-9.52%	-47.05%
SANA Sana Biotechnology	0.00%	-4.23%	+18.30%	-39.46%	-80.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.0823 of 5 stars	3.6	1.0	0.0	0.0	2.7	4.2	1.3
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	4.357 of 5 stars	4.0	2.0	0.0	4.0	2.7	1.7	1.3
SANA Sana Biotechnology	1.8729 of 5 stars	3.4	0.0	0.0	0.0	1.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.13	Buy	$9.67	109.69% Upside
BHST BioHarvest Sciences	3.00	Buy	$13.67	112.22% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.81	34.34% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	496.69% Upside

Current Analyst Ratings Breakdown

Latest BHST, SAGE, AMLX, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $16.00
5/7/2025	AMLX Amylyx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $10.00
5/6/2025	AMLX Amylyx Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/8/2025	BHST BioHarvest Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/7/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$3.00 ➝ $7.00
3/18/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/18/2025	SANA Sana Biotechnology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00
3/14/2025	SANA Sana Biotechnology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00

(Data available from 5/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	-$1.27M	-322.86	$0.84 per share	5.51	$6.42 per share	0.72
BHST BioHarvest Sciences	$25.19M	4.20	N/A	N/A	($1.08) per share	-5.96
SAGE Sage Therapeutics	$47.40M	8.67	N/A	N/A	$7.56 per share	0.87
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	$49.27M	-$3.11	N/A	N/A	N/A	N/A	-36.97%	-29.61%	N/A
BHST BioHarvest Sciences	-$12.56M	-$0.72	N/A	N/A	N/A	-76.65%	N/A	-85.16%	5/15/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-971.50%	-68.18%	-60.84%	7/30/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$0.88	N/A	N/A	N/A	N/A	-84.22%	-44.97%	5/14/2025 (Estimated)

Latest BHST, SAGE, AMLX, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	N/A	N/A	N/A	$7.80 million	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million
3/31/2025	Q4 2024	BHST BioHarvest Sciences	-$0.12	-$0.17	-$0.05	-$0.17	$7.24 million	$7.17 million
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A
3/4/2025	Q4 2024	AMLX Amylyx Pharmaceuticals	-$0.49	-$0.55	-$0.06	-$0.55	N/A	($0.67) million
2/11/2025	Q4 2024	SAGE Sage Therapeutics	-$1.54	-$1.56	-$0.02	-$1.56	$14.37 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	$1.02	22.04%	N/A	N/A	N/A
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	4.55	4.55
BHST BioHarvest Sciences	N/A	0.80	0.48
SAGE Sage Therapeutics	N/A	7.42	7.42
SANA Sana Biotechnology	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
BHST BioHarvest Sciences	N/A
SAGE Sage Therapeutics	99.22%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
BHST BioHarvest Sciences	N/A
SAGE Sage Therapeutics	5.50%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.08 million	60.53 million	Optionable
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
SAGE Sage Therapeutics	690	62.62 million	58.10 million	Optionable
SANA Sana Biotechnology	380	225.48 million	153.83 million	Optionable

BHST, SAGE, AMLX, and SANA Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers SANA

May 10 at 9:07 AM | accessnewswire.com

SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

May 9 at 7:00 PM | accessnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit – SANA

May 9 at 4:30 PM | accessnewswire.com

SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 9 at 4:00 PM | globenewswire.com

Investors Who Lost Money on Sana Biotechnology, Inc. (SANA) Should Contact Levi & Korsinsky about Pending Class Action - SANA

May 9 at 8:30 AM | accessnewswire.com

Sana Biotechnology (SANA) Expected to Announce Earnings on Wednesday

May 9 at 8:19 AM | marketbeat.com

Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky

May 9 at 7:30 AM | accessnewswire.com

Compass Rose Asset Management LP Increases Stock Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

May 9 at 7:08 AM | marketbeat.com

SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

May 9 at 7:00 AM | accessnewswire.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Crestline Management LP

May 9 at 6:31 AM | marketbeat.com

Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline

May 9 at 5:45 AM | prnewswire.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Marshall Wace LLP

May 9 at 3:36 AM | marketbeat.com

Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact Levi & Korsinsky about pending Class Action - SANA

May 8 at 9:20 PM | accessnewswire.com

SANA SHAREHOLDER ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA

May 8 at 9:09 PM | accessnewswire.com

Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

May 8 at 5:30 PM | accessnewswire.com

Shareholders That Lost Money on Sana Biotechnology, Inc. (SANA) Should Contact Levi & Korsinsky About Pending Class Action - SANA

May 8 at 4:30 PM | accessnewswire.com

SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

May 8 at 1:44 PM | globenewswire.com

Lost Money on Sana Biotechnology, Inc.(SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

May 8 at 8:25 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

May 8 at 8:00 AM | accessnewswire.com

Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA

May 8 at 7:30 AM | accessnewswire.com

SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

May 8 at 7:00 AM | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST, SAGE, AMLX, and SANA Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$4.61 +0.03 (+0.66%)

As of 05/9/2025 03:58 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

BioHarvest Sciences NASDAQ:BHST

$6.44 -0.03 (-0.46%)

As of 05/9/2025 03:34 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Sage Therapeutics NASDAQ:SAGE

$6.56 -0.15 (-2.24%)

As of 05/9/2025 04:00 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$1.81 0.00 (0.00%)

As of 05/9/2025 03:58 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time